ClinicalTrials.gg
TerminatedNCT01080768Updated Dec 26, 2011Results posted

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

A Phase 2 interventional study of Aliskiren/amlodipine and Amlodipine in Hypertension and Ankle Edema, sponsored by Novartis Pharmaceuticals. Terminated at 9 sites in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-12-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Publication of data from a similar study made the current study redundant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
75th of 89
31 · median 253
Started
2010
with 13 others
Phase 2
8 of 89
none open now
Registered
66th of 89
by date
Lead sponsor
12 of 89
Novartis Pharmaceuticals

Among the 89 studies testing aliskiren in Hypertension, this one is the 75th largest by enrollment, is one of 14 that started in 2010, is one of 8 in phase 2, and was the 66th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

The purpose of the present study was to evaluate the addition of aliskiren, to amlodipine can attenuate ankle edema formation in hypertensive patients.

03

Conditions studied

  • Hypertension
  • Ankle Edema

Browse trials for

Keywords

  • Pedal edema
  • hypertension
  • aliskiren
  • amlodipine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (male or female) with hypertension aged between 18-75 yrs.
  • Patients not treated with amlodipine or no amlodipine in previous 1 year.
  • females

Exclusion criteria

Exclusion Criteria:

  • Patients unable to switch from prior hypertensive medication.
  • Severe hypertension.
  • Pregnant or nursing females.
  • Patients with Type 1 or Type 2 diabetes mellitus
  • History of immunodeficiency diseases, including a positive (HIV) (Enzyme-linked immunosorbent assay [ELISA] and Western blot) test result.
  • A positive surface antigen (HBsAg) or test result.

Other protocol-defined inclusion/exclusion criteria are applied

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Aliskiren/amlodipine + Placebo to amlodipine

    During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine. The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

    Drug: Aliskiren/amlodipine · Drug: Placebo to Amlodipine

  • Active comparator
    Amlodipine + Placebo to aliskiren/amlodipine

    During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day. The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

    Drug: Amlodipine · Drug: Placebo to Aliskiren/amlodipine

Interventions

  • DrugAliskiren/amlodipine

    Drug pages: AliskirenStudies of AliskirenAliskiren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aliskiren/amlodipine 150/5 mg/day

    Also known as: SPA100

  • Amlodipine 5 mg/day.

  • DrugPlacebo to Aliskiren/amlodipine

    Placebo to Aliskiren/amlodipine 150/10 mg/day

  • DrugPlacebo to Amlodipine

    Placebo to Amlodipine 5 mg/day

06

What researchers measure

Primary outcomes

  1. Change in the Ankle Foot Volume (AFV) as Measured by Displacement Method

    AFV (mL) was measured using the principle of water displacement using a commercially available foot volumeter. The amount of water displaced in milliliters (mL) equals the volume of the foot/ankle. The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.

    Time frame: Baseline, 4 weeks

07

Results

Posted Dec 26, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren/Amlodipine + Placebo to AmlodipineAmlodipine+ Placebo to Aliskiren/Amlodipine
Started1417
Completed1216
Not completed21
Withdrew: Protocol deviation21

Outcome measures

PrimaryChange in the Ankle Foot Volume (AFV) as Measured by Displacement Method

AFV (mL) was measured using the principle of water displacement using a commercially available foot volumeter. The amount of water displaced in milliliters (mL) equals the volume of the foot/ankle. The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · mL

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren/Amlodipine and Placebo to Amlodipine—0/14 (0%)2/14 (14.3%)
Amlodipine and Placebo to Aliskiren/Amlodipine—0/17 (0%)2/17 (11.8%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAliskiren/Amlodipine and Placebo to AmlodipineAmlodipine and Placebo to Aliskiren/Amlodipine
DizzinessNervous system disorders2/140/17
Abdominal painGastrointestinal disorders1/140/17
Otitis externaInfections and infestations1/140/17
Back painMusculoskeletal and connective tissue disorders1/141/17
HeadacheNervous system disorders1/140/17
Musculoskeletal painMusculoskeletal and connective tissue disorders1/140/17
Pain in extremityMusculoskeletal and connective tissue disorders1/140/17
DyspnoeaRespiratory, thoracic and mediastinal disorders1/140/17
PalpitationsCardiac disorders1/140/17
Gastrooesophageal reflux diseaseGastrointestinal disorders0/141/17

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren/Amlodipine + Placebo to AmlodipineAmlodipine+ Placebo to Aliskiren/AmlodipineTotal
Mean55.4 ± 6.2158.0 ± 4.4956.8 ± 5.40
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren/Amlodipine + Placebo to AmlodipineAmlodipine+ Placebo to Aliskiren/AmlodipineTotal
Female549
Male91322
08

Study locations

9 sites
  • Novartis Investigative Site
    Beek en Donk, Netherlands
  • Novartis Investigative Site
    Bosch, Netherlands
  • Novartis Investigative Site
    Den Haag, Netherlands
  • Novartis Investigative Site
    Hoogwoud, Netherlands
  • Novartis Investigative Site
    Lichtenvoorde, Netherlands
  • Novartis Investigative Site
    Lieshout, Netherlands
  • Novartis Investigative Site
    Poortvliet, Netherlands
  • Novartis Investigative Site
    Utrecht, Netherlands
  • Novartis Investigative Site
    Wildervank, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2010
First posted
Mar 4, 2010
Start
Feb 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Dec 26, 2011
Last update
Dec 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01080768
Responsible party
Sponsor
First posted
Mar 4, 2010
Start date
Feb 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Dec 26, 2011
Last update
Dec 26, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine

Start the discussion